Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024
Elutia (Nasdaq: ELUT), a drug-eluting biomatrix products company, has scheduled its third quarter 2024 financial results release for Thursday, November 14, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. Management will be available for discussion, and investors can access the call through U.S. (877-407-8029) or International (201-689-8029) numbers using Conference ID 13749386.
Elutia (Nasdaq: ELUT), un'azienda che produce biomatrici medicamentose, ha programmato il rilascio dei suoi risultati finanziari del terzo trimestre 2024 per giovedì 14 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call e un webcast alle 16:30 ora orientale lo stesso giorno. La direzione sarà disponibile per discussioni e gli investitori potranno accedere alla chiamata attraverso i numeri statunitensi (877-407-8029) o internazionali (201-689-8029) utilizzando l'ID conferenza 13749386.
Elutia (Nasdaq: ELUT), una compañía de productos biométricos con liberación de fármacos, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el jueves 14 de noviembre de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m. hora del Este el mismo día. La dirección estará disponible para discusiones y los inversores podrán acceder a la llamada a través de los números de EE. UU. (877-407-8029) o internacionales (201-689-8029) utilizando el ID de conferencia 13749386.
엘루티아 (Nasdaq: ELUT), 약물 방출 바이오 매트릭스 제품 회사,는 2024년 3분기 재무 결과 발표를 2024년 11월 14일 목요일, 시장 마감 후로 예정했습니다. 회사는 같은 날 오후 4시 30분 동부 표준시 기준으로 컨퍼런스 콜 및 웹캐스트를 개최합니다. 경영진이 논의를 위해 참석하며, 투자자들은 미국(877-407-8029) 또는 국제(201-689-8029) 번호를 통해 컨퍼런스 ID 13749386을 사용하여 전화를 통해 접근할 수 있습니다.
Elutia (Nasdaq: ELUT), une entreprise de produits biomatriques à libération de médicaments, a prévu de publier ses résultats financiers du troisième trimestre 2024 pour le jeudi 14 novembre 2024, après la fermeture des marchés. L'entreprise organisera une conférence téléphonique et un webcast à 16h30, heure de l'Est, le même jour. La direction sera disponible pour des discussions, et les investisseurs pourront accéder à l'appel via les numéros aux États-Unis (877-407-8029) ou internationaux (201-689-8029) en utilisant l'ID de conférence 13749386.
Elutia (Nasdaq: ELUT), ein Unternehmen für Arzneimittel-freisetzende Biomatrixprodukte, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für Donnerstag, den 14. November 2024, nach Börsenschluss geplant. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast durchführen. Das Management steht für Diskussionen zur Verfügung, und Investoren können über die US-Nummer (877-407-8029) oder die internationale Nummer (201-689-8029) unter Verwendung der Konferenz-ID 13749386 anrufen.
- None.
- None.
SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.
The conference call can be accessed using the following information.
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13749386
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
When will Elutia (ELUT) release Q3 2024 earnings?
What time is Elutia's (ELUT) Q3 2024 earnings call?
How can investors access Elutia's (ELUT) Q3 2024 earnings call?
